Please assess the completion status of the following clinical trial:

Trial Title: Efficacy and Safety Trial of RPC1063 for Moderate to Severe Crohn's Disease

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Key Inclusion Criteria:~* Crohn's disease (CD) confirmed by endoscopy and histology~* Active disease as evaluated by Crohn's Disease Activity Index Score and Simple Endoscopic Score for CD~* Inadequate response to aminosalicylates, corticosteroids, immunomodulators or biologic therapy~Key Exclusion Criteria:~* Diagnosis of ulcerative colitis or indeterminate colitis~* Known strictures/stenosis leading to symptoms of obstruction~* Current stoma or need for ileostomy or colostomy~* Clinically relevant cardiovascular conditions or other relevant diseases that could impact the implementation or interpretation of the trial, or put the patient at risk~* History of uveitis or known macular edema~* History of colonic dysplasia

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 75 Years
- Healthy Volunteers: f

Study Arms:
- RPC1063 (Ozanimod) (Type: EXPERIMENTAL): None

Based on this trial design, predict the completion outcome and termination type (if applicable).